Advanced RCC Update from ESMO 2025 скачать в хорошем качестве

Advanced RCC Update from ESMO 2025

Prof. Viktor Grünwald joined us at ESMO 2025 to share his insights into how new renal cell carcinoma data presented at the meeting might impact clinical practice.  Studies mentioned in this video:   LenCabo: A randomised, phase 2, multicenter trial of lenvatinib plus everolimus vs cabozantinib in patients with metastatic ccRCC that progressed on PD-1 immune checkpoint inhibition. Hahn A, et al.  Abstract LBA94, ESMO 2025  KEYMAKER-U03: First-line pembrolizumab-based regimens for advanced ccRCC: KEYMAKER-U03 substudy 03A. Suarez Rodriguez C, et al. Abstract LBA96, ESMO 2025  CLEAR: Final analysis of lenvatinib + pembrolizumab vs sunitinib in patients with aRCC with or without bone metastases in CLEAR. Guglielmo Porta C, et al. Abstract 2603P, ESMO 2025  CAIX PET/CT: 68Ga]Ga-DPI-4452 PET/CT for staging of patients with ccRCC. Küper AT, et al. Abstract 2597MO, ESMO 2025    Clinical Takeaways LenCabo: demonstrates the efficacy of lenvatinib + everolimus for ICI pre-treated RCC patients with improved PFS & ORR compared with cabozantinib, although with higher toxicity. This combination should be considered for patients needing rapid or high tumour response for whom the higher toxicity rate is acceptable CLEAR: Lenvatinib + pembrolizumab demonstrated improved efficacy versus sunitinib in advanced RCC, regardless of the presence or absence of bone metastases and continues to be a standard of care treatment in this population KEYMAKER-U03: Among various combinations tested, adding belzutifan (a HIF-2α inhibitor) to lenvatinib and pembrolizumab was the only regimen with improved PFS, response durability, and OS—supporting advancement to phase 3 trials as a promising new triplet for 1st-line RCC CAIX PET/CT: Ga-DPI PET provides high-resolution, tumour-specific imaging in clear cell RCC, enhancing distinction between oligometastatic and widespread disease and enabling more precise selection for multimodality treatments Get more updates from ESMO 2025 in bladder cancer, NSCLC, breast, gynecological and upper GI cancers on our website: https://cor2ed.com/n-connect/programm...   Follow GU CONNECT on social media:   X - https://x.com/guconnectinfo    LinkedIn -   / gu-connect        Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.  This content is intended for healthcare professionals only.   This programme is financially supported by an independent educational grant from Eisai Europe Limited. Eisai has financially contributed towards this material as a sponsor and has had no influence in its organisation or creation. This video was developed by cor2ed.com  Published October 2025